Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

AGN 193109

Catalog No: tcsc0035405

Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg

Specifications

CAS No:
171746-21-7

Formula:
$C_{28}H_{24}O_2$

Pathway:
Metabolic Enzyme/Protease

Target:
RAR/RXR

Purity / Grade:
>98%

Solubility:
DMSO : 2 mg/mL (5.10 mM; Need warming)

Observed Molecular Weight:
392.49

Product Description

AGN 193109 is a retinoid analog, and acts as a specific and highly effective antagonist of **retinoic acid receptors (RARs)**, with $\mathbf{K_d}$s of 2 nM, 2 nM, and 3 nM for **RARα**, **RARβ**, and **RARγ**, respectively.

Copyright 2021 Taiclone Biotech Corp.

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

IC50 & Target: Kd: 2 nM (RARα), 2 nM (RARβ), 3 nM (RARγ)[1]

In Vitro: AGN 193109 is a highly effective antagonist of retinoic acid receptors, with K_ds of 2 nM, 2 nM, and 3 nM for RARα, RARβ, and RARγ, respectively. AGN 193109 is completely RAR specific, because it does not bind to or transactivate through any of the RXRs [1]. AGN 193109 (100 nM) inhibits the TTNPB (a retinoic acid receptor agonist)-dependent morphological change in ECE16-1 cells. AGN193109 half-reverses retinoid-dependent growth suppression at 10 nM, and completely shows this effect at 100 nM in ECE16-1 cells. AGN193109 (100 nM) also eliminates TTNPB-induced decrease in levels of K5, K6, K14, K16, and K17 and increase in levels of K7, K8, and K19[2].

In Vivo: AGN 193109 (1.15 μmol/kg) does not causes overt toxicity and has no effect on spleen weight on the mice, but it suppresses TTNPB-induced increase in spleen weight of the mice. AGN 193109 also significantly reduces the cutaneous toxicity induced by ATRA. AGN 193109 (0.30 or 1.20 μmol/kg) by topical treatment significantly reduces both weight loss and cutaneous toxicity caused by oral TTNPB cotreatment[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.